Cargando…
Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer. Although the possible availability of...
Autores principales: | Roviello, Giandomenico, D'Angelo, Alberto, Roudi, Raheleh, Petrioli, Roberto, Mini, Enrico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637676/ https://www.ncbi.nlm.nih.gov/pubmed/31354820 http://dx.doi.org/10.1155/2019/5692317 |
Ejemplares similares
-
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020) -
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020) -
p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis
por: Sobhani, Navid, et al.
Publicado: (2021) -
FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
por: Catalano, Martina, et al.
Publicado: (2020) -
The Hepatitis B Vaccine and Celiac Disease: More Lights Than Shadows?
por: Vitaliti, Giovanna, et al.
Publicado: (2013)